farmatic biotech energy ag
farmatic biot. energy ag english
Capital increase approved
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
Capital increase approved
Within the context of corporate restructuring the executive board of farmatic
biotech energy ag has developed a solid financing concept in cooperation with
lending institutes and a strategic investor that will secure the realization of
important ongoing and future projects. In addition to the provision of an
adequate volume of loan capital, the injection of new equity capital has also
been planned. Company administration has decided to increase equity by issuing
800,000 new shares (9% of increased capital stock) to be acquired by a
strategic investor. According to the resolution of the general meeting of
shareholders, the capital increase will be drawn from approved capital and will
not offer subscription rights. The company will receive EUR 1.0 million in
return for the shares issued.
Following the new orientation of operational business activities, the
implementation of cost cutting measures and the optimization of organization
structures, the adopted financial concept is the last decisive element in the
restructuring of farmatic. With these moves, the new management team has
successfully laid the foundation for the company’s future positive
developments.
Contact: Vibeke Dons, Corporate communication
farmatic biotech energy ag, Kolberger Strasse 13, D-24589 Nortorf
Tel.: +49 (4392) 9177-200, Fax: -197
dons@farmatic.com, http://www.farmatic.com
end of ad-hoc-announcement (c)DGAP 26.03.2003
——————————————————————————–
WKN: 605192 ; ISIN: DE0006051923; Index:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart
261627 Mär 03
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found